Intermittent fasting and changes in Galectin-3: a secondary analysis of a randomized controlled trial of disease-free subjects
An HbA1c target of less than 7.0% was attained by up to 80% with high-dose GLP-1 receptor agonists and up to 97% with tirzepatide (GLP-1/GIP receptor agonist), with even up to 62% of people with T2D reaching an HbA1c of less than 5.7%
A significant positive correlation between enteral length and Bristol stool score was demonstrated in all studied patients and a distinct positive one in the group who received KD with L-carnitine supplementation indicating that an increase in antral length was associated with higher Bristol stool score thus a softer stool consistency
These treatments deliver essential vitamins and minerals to your cells, enhancing your immune system, blood circulation, and healing processes
The Australia GLP-1 receptor agonist market size accounted for USD 570.49 million in 2025 and is predicted to increase from USD 652.07 million in 2026 to approximately USD 2,117.46 million by 2035, expanding at a CAGR of 14.01% from 2026 to 2035
